Immix Biopharma (IMMX) Operating Leases (2024 - 2026)

Quarterly results put Operating Leases at $912343.0 for Q1 2026, down 7.95% from a year ago — trailing twelve months through Mar 2026 was $912343.0 (down 7.95% YoY), and the annual figure for FY2025 was $933625.0, down 7.52%.

Immix Biopharma has reported Operating Leases over the past 3 years, most recently at $912343.0 for Q1 2026.

  • Operating Leases reached $912343.0 in Q1 2026 per IMMX's latest filing, down from $933625.0 in the prior quarter.
  • Across five years, Operating Leases topped out at $1.1 million in Q1 2024 and bottomed at $912343.0 in Q1 2026.
  • Median Operating Leases over the past 3 years was $991126.0 (2025), compared with a mean of $990235.6.
  • The largest annual shift saw Operating Leases decreased 5.97% in 2025 before it dropped 7.95% in 2026.
  • Over 3 years, Operating Leases stood at $1.0 million in 2024, then decreased by 7.52% to $933625.0 in 2025, then dropped by 2.28% to $912343.0 in 2026.
  • Business Quant data shows Operating Leases for IMMX at $912343.0 in Q1 2026, $933625.0 in Q4 2025, and $965053.0 in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Quantum Biopharma 1,384,976.65 Bn 1,384,976.64 Bn -
2 Alterity Therapeutics 777,208.84 Bn 777,208.81 Bn -
3 Legend Biotech 2,801.00 Bn 2,800.10 Bn 242.10 Mn
4 Nanobiotix 2,226.01 Bn 2,225.95 Bn -
5 Akari Therapeutics 605.66 Bn 605.66 Bn -
6 Vertex Pharmaceuticals 110.17 Bn 102.92 Bn 2.59 Bn
7 Regeneron Pharmaceuticals 66.86 Bn 58.11 Bn 3.31 Bn
8 Evaxion A 65.12 Bn 65.10 Bn -
9 Alnylam Pharmaceuticals 39.94 Bn 36.94 Bn 959.66 Mn
10 Immix Biopharma 476.17 Mn 476.17 Mn -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 912,343.00
Dec 31, 2025 933,625.00
Sep 30, 2025 965,053.00
Jun 30, 2025 972,335.00
Mar 31, 2025 991,126.00
Dec 31, 2024 1.01 Mn
Sep 30, 2024 1.03 Mn
Jun 30, 2024 1.04 Mn
Mar 31, 2024 1.06 Mn